Wu Y, Zhang C, Xiong J, Cai D, Wang C, Liu Y, et al. Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate. Cell Res. 2023;33:835-850 pubmed publisher

Chebotarev A, Ledyaeva V, Patsap O, Ivanov A, Fedotov A, Belousov V, et al. Multimodal label-free imaging of murine hepatocellular carcinoma with a subcellular resolution. J Biophotonics. 2023;16:e202300228 pubmed publisher

Zhu C, Soto Feliciano Y, Morris J, Huang C, Koche R, Ho Y, et al. MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. elife. 2023;12: pubmed publisher

Kido T, Lau Y. Androgen receptor variant 7 exacerbates hepatocarcinogenesis in a c-MYC-driven mouse HCC model. Oncogenesis. 2023;12:4 pubmed publisher

Mulero S xe1 nchez A, Ramirez C, du Chatinier A, Wang H, Koomen S, Song J, et al. Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Mol Oncol. 2023;17:964-980 pubmed publisher

Abakumova T, Vaneev A, Naumenko V, Shokhina A, Belousov V, Mikaelyan A, et al. Intravital electrochemical nanosensor as a tool for the measurement of reactive oxygen/nitrogen species in liver diseases. J Nanobiotechnology. 2022;20:497 pubmed publisher

Feng G, Sun H, Piao M. FBXL6 is dysregulated in keloids and promotes keloid fibroblast growth by inducing c-Myc expression. Int Wound J. 2022;: pubmed publisher

Zheng C, Liang S, Liu B, Liu P, Kwan S, Wolfe S, et al. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol Ther. 2022;30:1343-1351 pubmed publisher

Du L, Liu W, Aldana Masangkay G, Pozhitkov A, Pichiorri F, Chen Y, et al. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. J Exp Clin Cancer Res. 2022;41:8 pubmed publisher

Jin H, Shi Y, Lv Y, Yuan S, Ramirez C, Lieftink C, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595:730-734 pubmed publisher

Liu P, Liang S, Zheng C, Mintzer E, Zhao Y, Ponnienselvan K, et al. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat Commun. 2021;12:2121 pubmed publisher

Jiang T, Sanchez Rivera F, Soto Feliciano Y, Yang Q, Song C, Bhuatkar A, et al. Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Hepatology. 2021;74:233-247 pubmed publisher

Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, et al. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1. Cell Commun Signal. 2020;18:100 pubmed publisher

Leibold J, Ruscetti M, Cao Z, Ho Y, Baslan T, Zou M, et al. Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. Cancer Discov. 2020;10:1038-1057 pubmed publisher

Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019;: pubmed publisher

Liu X, Song X, Zhang J, Xu Z, Che L, Qiao Y, et al. Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma. Cancer Med. 2018;7:6170-6181 pubmed publisher

Liu P, Ge M, Hu J, Li X, Che L, Sun K, et al. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017;66:167-181 pubmed publisher